Primary and secondary prevention of myocardial infarction

Clinical and Experimental Hypertension

Volumn 18, Issue 3-4, 1996, Pages 547-558

  Borghi, Claudio ^a   Ambrosioni, Ettore ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ace inhib itors; aspirin; cholesterol; hypertension; myocardial infarction; risk; blockers

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; PATHOGENESIS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 0029871719     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969609088984     Document Type: Conference Paper

References (23)

1. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992;2:113-156
2. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med 1992;326:140-1416
3. Pyorala K, DE Baker G, Graham P, Poole-Wilson P, Wood D on behalf of the Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-1331; Atherosclerosis 1994;110:121-161
4. Pyorala K, DE Baker G, Graham P, Poole-Wilson P, Wood D on behalf of the Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-1331; Atherosclerosis 1994;110:121-161
5. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease. Part 1. Lancet 1990:335;765-774
6. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. Part 2. Lancet 1990:335; 827-838
7. Fang J, Madhavan S, Cohen H, Alderman MH. Measures of blood pressure and myocardial infarction in treated hypertensive patients. J Hypertens 1995; 13:413-419
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA 1991;265:3255-3264
9. Siliberg JS, Henry DA. The benefit of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1.A meta-analysis of cholesterol lowering trials. Med J Aust 1991: 155;665-670
10. Samuelsson O, Wilhelmsen L, Andersson OK. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the Primary Prevention Trial in Goteborg, Sweden. JAMA 1987: 258: 1768-1775
11. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707
12. Rossouw JE, Lewis B, Rifkind BM. The value of lowring cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112-1119
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowring in 4444 patients with coronary heart disease: the Scandinavia Simvassatin Survival Study (4S). Lancet 1994; 344: 1383-1389
14. Browner WS, Hulley SB. Effect of risk status on treatment criteria. Implications in hypertension trials. Hypertension 1989; 13(suppl I): 1-51 - 1-56
15. Rutherford JD, Pfeffer MA, Moyè LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miler HS, Paxker M, Rouleau JL, Braunwald MD on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Reuslts of the Survival and Ventricular Enlargement Trial. Circulation 1994; 90: 1731-1738
16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371
17. The BBPP Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post-infarction patients. Eur Heart J 1988; 9; 8-16
18. Yusuf S, Wittes J, Friedman L. Overview of results of randomised clinical trials in heart disease. 1. Treatments following myocardial infarction. JAMA 1988; 260: 2088-2093
19. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet therapy.- I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Lancet 1994; 308:81-106
20. Pfeffer MA, Braunwald E,Moyè LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677
21. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992;340:1173-1178
22. Wright RA, Flapan AD, Simpron CC, Stenhouse F, Oliver F, Ludiam CA, Fox AA. Effects of captopril on endogeneous fibrinolysis in patients with recent myocardial infarction. A double-blind randomized placebo controlled cross-over study. JACC 1994;113A
23. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen Activator Inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9